Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab.
about
European evidence based consensus on the diagnosis and management of Crohn's disease: special situationsClinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent updateInfliximab-Related Infusion Reactions: Systematic ReviewCystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab.The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations.Infliximab therapy in pediatric Crohn's disease: a review.Inflammatory bowel disease associated arthropathyEffectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF-αVariability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins.Managing complicated Crohn's disease in children and adolescents.Infliximab therapy for pediatric Crohn's disease.Short-term response to adalimumab in childhood inflammatory bowel disease.Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel diseaseTargeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Pediatric ulcerative colitis: current treatment approaches including role of infliximab.Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.Infliximab for the treatment of pediatric ulcerative colitis.Characterisation of aptamers for therapeutic studies.Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment responseThe role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.Safety of TNF inhibitors in adolescents and children.Anti-TNF therapeutics for the treatment of sarcoidosis.The Role of Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Alpha Agents in Children and Adolescents with Inflammatory Bowel Disease.Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?Micheliolide, a new sesquiterpene lactone that inhibits intestinal inflammation and colitis-associated cancer.Alternative Anaphylactic Routes: The Potential Role of MacrophagesImmunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.Therapeutic Drug Monitoring in Children and Young Adults With Inflammatory Bowel Disease: A Practical Approach.Update on bioagent therapy in sarcoidosis.Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium.Infliximab treatment in a paediatric patient with ulcerative colitis, who developed acute pancreatitis due to azathioprine during follow-up.A survey of applications of biological products for drug interference of immunogenicity assays.Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease.Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab.Infliximab drug and antibody levels in patients with dermatological conditions.What are the guidelines for using biologics in pediatric patients?
P2860
Q22242050-73243464-B61D-4DA5-B254-BD45911488FCQ26994776-1F52A5F0-7594-4E95-911E-D50494F9DA45Q27013835-DA91A719-2281-4BCC-8457-7BBE907674B0Q33798912-D21C080B-5F90-4342-9BB7-13BBFB39E29AQ34152778-2F31DBF5-2324-447A-B4CA-27A78D3B5B88Q35026358-338504C2-513D-41EE-A0B1-ED7C2E5525FCQ35680638-CABFAC51-B9E1-4754-AB5F-CFCEEBCC8BA2Q35954116-7C6A9DEF-EFEF-4C06-85A0-4B6E1D3C05E6Q36231590-F55A42B0-8642-4D5A-9E2E-8202F6494A5CQ36269608-54A5E1B8-0548-4FEE-BD7D-3F63A9964165Q36331225-FEFCDC81-BE38-4B95-B50A-C47B5A686E33Q37012073-4D0C8DFB-AC3C-4A95-A83F-AA8F6223F43EQ37212946-429E3441-9684-4D4F-8941-87E21DC4B3DCQ37609746-591C1752-AE3E-4BC4-A596-9B11D56C5A88Q37690479-A29E093F-D9A8-43C3-884A-8594BF124F00Q37936394-B6A1E7E7-9CE7-44E8-AB67-017B087CCA3BQ38022238-9DCC05A2-E7C1-4BDA-A12B-7F72EEF00840Q38059422-92DB3C97-7F27-47F6-8076-92256D4D97BDQ38067127-8F79ECD2-2209-4FE0-8677-DA50D40E3EDEQ38089865-DD4852F5-ADD0-4076-9F9B-15E267E6FBB8Q38118313-DAAD843F-9229-475D-97B2-7592F0C2BF20Q38129037-5C312E15-F0B4-4F17-893C-4E07142D5086Q38166552-4E90E180-3F4D-4CE3-A0F4-4EFF20C2B2C0Q38193792-BDCDE3F9-6896-427F-AF0F-B65DC50E9423Q38271881-7E7DC05A-07DB-4887-A47B-A7F0E46070F0Q38568813-9F1F71C9-F12F-4790-A5A8-320E4835F0BDQ38631012-C9AABC9E-A23B-4649-862D-0D2C8C322E39Q38971107-E93B3CFB-5151-42DC-BC39-0D079BDD7CEAQ39323741-242B974C-3F63-4C1D-AA35-4F3636BD62FEQ39371316-AB0BACE8-9E5A-435D-940C-E10D64F33D4FQ39834984-62DF8247-169B-4706-B1C6-35FA299B2FC8Q42415512-DF833253-3A8D-488F-B7B0-3C46F40C27F0Q46469250-6B27E9AA-CFB7-46AE-8A61-1D7D6888CD68Q47145064-EF72A118-1E67-4647-93B0-DDE84D531934Q47247174-D29EE3C8-4379-40ED-AFBF-5FA7891AECAEQ48185411-56690FB1-F5C2-47E2-BCAE-F8581805A445Q49109368-4CBFBF81-072F-410F-B3FC-3EF37B71AC6DQ50065301-DFFD53E3-16CF-4BEC-B1C1-2829BF6546F9Q50591592-96511BCA-4D2C-45CE-B9E4-1DD5AB1D8686Q53129698-EC90E559-D78A-437B-A958-17BC7768E9DE
P2860
Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Human antichimeric antibody in ...... disease receiving infliximab.
@ast
Human antichimeric antibody in ...... disease receiving infliximab.
@en
type
label
Human antichimeric antibody in ...... disease receiving infliximab.
@ast
Human antichimeric antibody in ...... disease receiving infliximab.
@en
prefLabel
Human antichimeric antibody in ...... disease receiving infliximab.
@ast
Human antichimeric antibody in ...... disease receiving infliximab.
@en
P2093
P1476
Human antichimeric antibody in ...... disease receiving infliximab.
@en
P2093
Erasmo Miele
Jonathan E Markowitz
Petar Mamula
Robert N Baldassano
P304
P356
10.1097/00005176-200405000-00008
P407
P577
2004-05-01T00:00:00Z